Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01843374 2026-03-05

Tremelimumab

571 enrolled 19 charts

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

301 enrolled 15 charts

Lung Cancer Metastatic

NCT03965468 2026-02-09

CHESS

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Mesothelioma

NCT05380713 2025-12-29

......SMARTEST Trial......

30 enrolled

Mesothelioma, Malignant

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03022500 2024-05-29

Pulmonary sarcomatoid_MEDI4736+Treme

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03994393 2023-04-21

ILLUMINATE

100 enrolled

EGFR Mutant Advanced Non Small Cell Lung Cancer

NCT03975114 2023-03-24

MILES-5

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02592551 2022-09-29

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

24 enrolled 22 charts

Mesothelioma

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn

Squamous Non-small Cell Lung Cancer

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

18 enrolled 13 charts

Small Cell Lung Carcinoma

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03130764 2017-12-06

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

40 enrolled

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

29 enrolled

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

29 enrolled

Mesothelioma, Malignant

NCT00312975 2012-06-07

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

90 enrolled